BR790 / Jiangxi Qingfeng Pharma - LARVOL DELTA

BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=90 | Not yet recruiting | Sponsor: Shanghai Gopherwood Biotech Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: Shanghai Gopherwood Biotech Co., Ltd.

Combination therapy • New P1/2 trial • Oncology • Solid Tumor

A Phase I Study of BR790 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Clinical • Monotherapy • New P1 trial • Oncology • Solid Tumor